• 1
    Batura D, Rao GG, Nielson PB. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment infections after biopsy. BJU Int 2010; 106: 10171020
  • 2
    Young JF, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 2009; 74: 332338
  • 3
    Loeb S, Van Den Heuvel S, Zhu X, Bangma CH, Shröder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 11101114
  • 4
    Liss MA, Chang A, Santos R et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 2011; 185: 12831288
  • 5
    American Urological Associated. Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis 2007. Available at:
  • 6
    Wolf JS Jr, Bennett CJ, Dmochowski RR et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179: 13791390
  • 7
    Nam RK, Saskin R, Lee Y et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 963967
  • 8
    Tal R, Livne PM, Lask DM et al. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol 2003; 169: 17621765
  • 9
    Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 2008; 14: 10411047
  • 10
    CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement. CLSI document M100-S21. Wayne: Clinical and Laboratory Standards Institute, 2011
  • 11
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864874
  • 12
    Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy – should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012; 18: 575581
  • 13
    Taylor AK, Zembower TR, Nadler RB et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012; 187: 12751279
  • 14
    Carignan A, Roussy J, Lapointe V, Valiquette L, Sabbagh R, Pépin J. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol 2012; 62: 453459
  • 15
    Feliciano J, Teper E, Ferrandino M et al. The incidence of fluoroquinolone resistant infections after prostate biopsy – are fluoroquinolones still effective prophylaxis? J Urol 2008; 179: 952955
  • 16
    Durham LK, Ge M, Cuccia AJ, Quinn JP. Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli. Eur J Clin Microbiol Infect Dis 2010; 29: 353356
  • 17
    Yagci D, Yoruk F, Azap A, Memikoglu O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in faecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009; 53: 12871289
  • 18
    Akduman B, Akduman D, Tokgöz H et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 2011; 78: 250255
  • 19
    Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011; 78: 511514
  • 20
    Batura D, Rao GG, Bo Nielsen P, Charlett A. Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 2011; 107: 760764